5:53 PM
 | 
Jan 09, 2009
 |  BC Extra  |  Clinical News

RegeneRx off after Phase II data

RegeneRx (AMEX:RGN) fell $0.76 (44%) to $0.99 on Friday after all three doses of RGN-137 missed the two key secondary efficacy endpoints of incidence...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >